US EditionNICE Recommends Mirikizumab for Crohn's Disease Treatment
Summary by pharmatimes.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
All
Left
Center
Right
Inflammatory bowel diseases (IIDs), such as ulcerative colitis and Crohn’s disease, affect thousands of people in Chile and the world, affecting their quality of life. These inflammatory bowel disorders have a multifactorial origin, although most studies determine that their origin is immune, in which the body “attacks” the cells of the digestive tract. To speak of Crohn and ulcerative colitis is to speak of intestinal inflammation, although bot…
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
